



## News Release

---

Media Contacts: Olivia Finucane  
(0044) 1992 452480

### **MSD Triumphs at National Awards Ceremony**

LOCATION, Hoddesdon, March 28, 2019 – MSD (tradename of Merck & Co., Inc., Kenilworth, N.J., USA (NYSE: MRK)) announced today that they had won four awards at the Pf Awards in London.

The Pf Awards, which are held annually, took place at the Royal Lancaster London Hotel and are the largest pharmaceutical sales awards in the UK.

Jack Worts, who works in the vaccines team, won two awards including the Future Leaders Award and Outstanding Performer; Neil MacDonald, Associate Director – Account Management Scotland, won the Joint Working Award; and Sam Singh, who works on the Diabetes team, won Primary Care Specialist.

Jack, Neil and Sam fought off tough competition to win the awards – with over four hundred entries being submitted this year by over thirty companies in the UK.

From the four hundred entries, two hundred were shortlisted to attend an assessment day which determined which finalists would attend on the night.

Jack said: “I am truly thrilled to have won the “Future Leader” and “Outstanding Performer” at this year’s Pf Awards. To be recognised by industry experts and winning this award based on the work that you do is a humbling feeling.

“There are many people who have contributed to my journey so far and without them this achievement wouldn’t have been possible. I am proud to work in this industry and for a company that plays such a pivotal role in helping to protect our population, past, present and future.”

Neil Mac Donald, who works in Account Management in Scotland, won the Joint Working Award for an initiative with the Scottish Ambulance Service, NHS Fife and Fife Diabetes Centre. The initiative saw paramedics being trained to better understand any knowledge gaps when conducting diabetes assessments and gather further patient information on call-outs, resulting in an almost forty per cent reduction in hospital admissions.

Neil said: “I am delighted and incredibly proud to work for MSD and to have been involved in this initiative with the Scottish Ambulance Service, NHS Fife and Fife Diabetes clinic. To win an award for this is an incredible honour.”

The training has resulted in a significant decrease in patients with diabetes being admitted to hospital, as they receive more cohesive standards of care. It has also resulted in the Scottish Ambulance Service increasing their knowledge and skillset about diabetes which has also had a positive impact on how they work, which highlights the importance of partnership working.”

Sam said: “I have always taken great pride in the relationships I build with healthcare professionals and truly believe that strong working relationships are key to improving outcomes for patients, the NHS and industry. The culture at MSD supports and encourages the desire to achieve such outcomes.

Diabetes is a growing challenge in the UK, and from a patient perspective I believe the condition should not define nor prohibit a normal lifestyle and that nobody should be denied the opportunity of living a normal healthy life.

The calibre of entrants within this category was astonishing; and to be recognised for my efforts in trying to make a difference is something that I am sincerely proud of.”

Louise Houson, MD for MSD in the UK and Ireland, said: “We are delighted that some of our team have received this external recognition for the great work that they do every day. As a

company we pride ourselves on the great people that work for us, who all believe in the vision of our company to save and improve lives. That's what gets them out of bed in the morning, and I am thrilled that this motivation, combined with their own personal contribution, has resulted in these awards.

Melanie Hamer, Director of Pf Awards said: "The PF Awards are a prestigious accolade for pharma's top talent to be measured against the rest of the industry. Congratulations to all the winners for the fantastic work they do. The standard of entries was incredibly high this year and all candidates should be proud of the difference they are making in the industry."

-ends-

### **About MSD**

For more than a century, MSD, a leading global biopharmaceutical company, has been inventing for life, bringing forward medicines and vaccines for the world's most challenging diseases. MSD is a trade name of Merck & Co., Inc., with headquarters in Kenilworth, N.J., U.S.A. Through our prescription medicines, vaccines, biologic therapies and animal health products, we work with customers and operate in more than 140 countries to deliver innovative health solutions. We also demonstrate our commitment to increasing access to health care through far-reaching policies, programmes and partnerships. Today, MSD continues to be at the forefront of research to advance the prevention and treatment of diseases that threaten people and communities around the world. For more information, visit [www.msd-UK.com](http://www.msd-UK.com) and connect with us on Twitter [@MSDintheUK](https://twitter.com/MSDintheUK).

### **Forward-Looking Statement of Merck & Co., Inc., Kenilworth, N.J., USA**

**(Please note: Bolded sentence is only included in product/pipeline news releases.)**

This news release of Merck & Co., Inc., Kenilworth, N.J., USA (the "company") includes "forward-looking statements" within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company's management and are subject to significant risks and uncertainties. **There can be no guarantees with respect to pipeline products that the products will receive the necessary regulatory approvals or that they will prove to be**

**commercially successful.** If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.

Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company's ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company's patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.

The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company's 2016 Annual Report on Form 10-K and the company's other filings with the Securities and Exchange Commission (SEC) available at the SEC's Internet site ([www.sec.gov](http://www.sec.gov)).

###